Finding tissue and blood markers that predict response to immunotherapy in recurrent or metastatic upper throat and mouth squamous cell cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional program collects tumor biopsies and blood samples from adults with recurrent or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx who are candidates for PD‑1 immunotherapy. Samples will be analyzed for histological and circulating markers to look for patterns associated with clinical response or progression. The work aims to link individual tumor heterogeneity to treatment outcomes to improve patient selection for immunotherapy. The project is carried out at multiple hospitals in Paris and requires informed consent and the ability to undergo biopsy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥ 18 years
* Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx
* Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy
* Patient affiliated to a health insurance plan
* French-speaking patient
* Patient with free, informed and written consent

Exclusion Criteria:

* Patients with a contraindication to immunotherapy (transplant patients)
* Pregnant or breast-feeding patients
* Patient under guardianship or curatorship
* Patient under court protection
* Patient deprived of liberty

Where it's running

• Hôpital Saint-Joseph
  Paris, France Recruiting
• Hôpital Bichat
  Paris, France Recruiting
• Hôpital Saint-Louis
  Paris, France Not yet recruiting

Study contacts

• Study coordinator: Eric Raymond, MD, PhD
• Email: eraymond@ghpsj.fr
• Phone: 144127883

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Platform for studying biomarkers and treatments in head and neck cancer

  This study is trying to gather information on how well different treatments work for people with advanced head and neck cancer to help improve future care.

  Recruiting AIO-Studien-gGmbH · Essen and 1 other locations · NCT06380686

• Reducing radiation therapy for head and neck cancer patients

  This study is testing if cutting back on radiation for head and neck cancer patients can help reduce side effects while still keeping the cancer under control.

  Recruiting Phase 2/3 University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT06030440

• Lower dose radiation therapy for HPV positive head and neck cancer

  This study is testing if a lower dose of radiation therapy can safely treat HPV positive head and neck cancer while causing fewer side effects.

  Recruiting at 3 sites Phase 2 University of Virginia · Miami, Florida and 4 other locations · NCT05962242

• Observing viral biomarkers and microRNAs in oropharyngeal tumors and occult cancers related to HPV

  This study is testing if certain viral markers and microRNAs in oropharyngeal tumors can help doctors better diagnose and monitor HPV-related cancers and find new treatments.

  Recruiting Regina Elena Cancer Institute · Rome · NCT05918510

• Personalized treatment for early-stage p16+ oropharyngeal cancer

  This study is testing two personalized treatment options for people with early-stage p16+ oropharyngeal cancer to see which one works best and is safer.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT05894083

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.